tetano
Editor, Senior Moderator
Hum Vaccin Immunother. 2015 Feb 18:0. [Epub ahead of print]
[h=1]Trivalent influenza vaccine-induced antibody response to circulating influenza a (H3N2) viruses in 2010/11 and 2011/12 seasons.[/h] Hiroi S[SUP]1[/SUP], Morikawa S, Nakata K, Maeda A, Kanno T, Irie S, Ohfuji S, Hirota Y, Kase T.
[h=3]Author information[/h]
[h=3]Abstract[/h] To evaluate antibody response induced by trivalent inactivated influenza vaccine (TIV) against circulating influenza A (H3N2) strains in healthy adults during the 2010/11 and 2011/12 seasons, a hemagglutination-inhibition (HI) assay was utilized to calculate geometric mean antibody titer (GMT), seroprotection rate (post vaccination HI titers of ≥1:40), and seroresponse rate (4-fold increase in antibody level). In the 2010/11 season, GMT increased 1.8- to 2.0-fold following the first dose of TIV against three circulating strains and 2.2-fold following the second compared to before vaccination. The seroresponse rate ranged from 22% to 26% following the first dose of TIV and from 31% to 33% following the second (n=54). The seroprotection rate increased from a range of 6% to 13% to a range of 26% to 33% following the first dose of TIV and to a range of 37% to 42% following the second (n=54). In the 2011/12 season, GMT increased 1.4-fold against A/Osaka/110/2011 and 1.8-fold against A/Osaka/5/2012. For A/Osaka/110/2011, the seroresponse rate was 29%, and the seroprotection rate increased from 26% to 55% following vaccination (n=31). For A/Osaka/5/2012, the seroresponse rate was 26%, and the seroprotection rate increased from 68% to 84% following vaccination (n=31). HI assays with reference antisera demonstrated that the strains in the 2011/12 season were antigenically distinct from vaccine strain (A/Victoria/210/2009). In conclusion, the vaccination increased the seroprotection rate against circulating H3N2 strains in the 2010/11 and 2011/12 seasons. Vaccination of TIV might have potential to induce reactive antibodies against antigenically distinct circulating H3N2 viruses.
[h=4]KEYWORDS:[/h] ACIP, Advisory Committee on Immunization Practices; Antibody; Circulating viruses; EMA, European Medicines Agency; GMT, geometric mean antibody titer; H3N2; HI, hemagglutination-inhibition; Influenza; TIV, trivalent inactivated influenza vaccine; Vaccine
PMID: 25692378 [PubMed - as supplied by publisher]
[h=1]Trivalent influenza vaccine-induced antibody response to circulating influenza a (H3N2) viruses in 2010/11 and 2011/12 seasons.[/h] Hiroi S[SUP]1[/SUP], Morikawa S, Nakata K, Maeda A, Kanno T, Irie S, Ohfuji S, Hirota Y, Kase T.
[h=3]Author information[/h]
[h=3]Abstract[/h] To evaluate antibody response induced by trivalent inactivated influenza vaccine (TIV) against circulating influenza A (H3N2) strains in healthy adults during the 2010/11 and 2011/12 seasons, a hemagglutination-inhibition (HI) assay was utilized to calculate geometric mean antibody titer (GMT), seroprotection rate (post vaccination HI titers of ≥1:40), and seroresponse rate (4-fold increase in antibody level). In the 2010/11 season, GMT increased 1.8- to 2.0-fold following the first dose of TIV against three circulating strains and 2.2-fold following the second compared to before vaccination. The seroresponse rate ranged from 22% to 26% following the first dose of TIV and from 31% to 33% following the second (n=54). The seroprotection rate increased from a range of 6% to 13% to a range of 26% to 33% following the first dose of TIV and to a range of 37% to 42% following the second (n=54). In the 2011/12 season, GMT increased 1.4-fold against A/Osaka/110/2011 and 1.8-fold against A/Osaka/5/2012. For A/Osaka/110/2011, the seroresponse rate was 29%, and the seroprotection rate increased from 26% to 55% following vaccination (n=31). For A/Osaka/5/2012, the seroresponse rate was 26%, and the seroprotection rate increased from 68% to 84% following vaccination (n=31). HI assays with reference antisera demonstrated that the strains in the 2011/12 season were antigenically distinct from vaccine strain (A/Victoria/210/2009). In conclusion, the vaccination increased the seroprotection rate against circulating H3N2 strains in the 2010/11 and 2011/12 seasons. Vaccination of TIV might have potential to induce reactive antibodies against antigenically distinct circulating H3N2 viruses.
[h=4]KEYWORDS:[/h] ACIP, Advisory Committee on Immunization Practices; Antibody; Circulating viruses; EMA, European Medicines Agency; GMT, geometric mean antibody titer; H3N2; HI, hemagglutination-inhibition; Influenza; TIV, trivalent inactivated influenza vaccine; Vaccine
PMID: 25692378 [PubMed - as supplied by publisher]